Antipsychotic-induced weight gain has emerged as a serious complication in the treatment of patients with most antipsychotics. We have conducted the first in-depth examination of dopamine receptor genes in antipsychoticinduced weight gain. A total of 206 patients (139 of European descent and 56 African Americans) who underwent treatment for chronic schizophrenia or schizoaffective disorder were evaluated after on average over 6 weeks of treatment. Thirty-six tag single nucleotide polymorphisms (SNPs) and one variable-number tandem repeat, spanning the five dopamine receptor genes (DRD1-DRD5) were analyzed. In the total sample, we found a nominally significant association between the DRD2 rs1079598 marker and weight change using a cutoff of 7% gain (P ¼ 0.03). When stratifying the sample according to ethnicity and antipsychotics with highest risk for weight gain, we found significant associations in three DRD2 SNPs: rs6277 (C957T), rs1079598 and rs1800497 (TaqIA). The other genes were primarily negative. We provide evidence that dopamine receptor DRD2 gene variants might be associated with antipsychotic-induced weight gain in chronic schizophrenia patients.
Introduction
Schizophrenia is a chronic and disabling neuropsychiatric disorder that afflicts approximately 1% of the general population. The use of atypical antipsychotic medication to treat schizophrenia symptoms is increasing, now capturing over 90% of the antipsychotic drug market in Canada and the United States. This increase is due to the consideration that atypical antipsychotics are associated with lower risk for extrapyramidal symptoms compared with typical neuroleptics. However, a major concern for the use of most atypical antipsychotics is weight gain. It occurs in approximately 30% of schizophrenia patients taking antipsychotic medication, and it often results in metabolic syndromes that include diabetes mellitus, dyslipidemia and hypertension, and represent a prominent risk for coronary heart disease, stroke and mortality. 1 These adverse effects have contributed to the high rate of treatment discontinuation in recent clinical trials. 2, 3 Obesity in the general population has been a major public health dilemma, and the association of atypical antipsychotics with weight gain adds to this problem. Concordance among twins suggests that the variability in weight gain induced by antipsychotic medication has a genetic component. 4, 5 Among genetic markers examined in antipsychotic-induced weight gain, two polymorphisms, the À759C/T polymorphism in serotonin receptor HTR2C gene, and the À2548G4A promoter polymorphism in the leptin gene, are most consistently associated with antipsychotic-induced weight gain (see references 6, 7, 8, 9 ; reviewed in Müller and Kennedy 1 ). Unexpected consumption and anticipation of primary (for example, food) and secondary (for example, drugs of abuse) reinforcers induce phasic dopamine release, which increases the motivation for further food-or drug-seeking. 10, 11 Chronic stimulation of dopaminergic neurotransmission by high-caloric food or drugs of abuse appears to induce homeostatic neuroadaptations, for example, in striatal dopamine receptor availability, which correlate with craving and reduced control of food and drug intake. 12, 13 Because all antipsychotic medications have common pharmacology at the dopamine system, 14 exploring whether dopamine receptors are involved in antipsychotic-induced weight gain is paramount. D1 antagonists have been shown to block amphetamine-induced anorexia-like phenotype, 15 whereas D2 antagonism is associated with increased feeding behavior. 16 Parkinson's disease patients treated with dopamine agonists (pramipaxole, for example) develop compulsive behaviors, including compulsive eating that is associated with significant weight gain.
17 D2 receptor density has been negatively correlated to body mass index. 18, 19 Genetically, the A1 (T) allele of the DRD2-associated Taq1A (rs1800497) polymorphism, which has been associated with reduced D2 levels, was associated with obesity. 20, 21, 22 Carriers of the A1 allele were found to have increased body weight, fat intake, saturated fat and cholesterol, and the A1 allele is associated with type 2 diabetes. 23 Interestingly, the TaqIA A1 allele is also associated with alcoholism, 24 nicotine dependence 25 and opiate dependence. 26 The C957T (rs6277) polymorphism is associated with alcohol dependence 27 and nicotine dependence. 28 Studies of the effects of the administration of olanzapine or clozapine in rodents have yielded mixed findings about weight gain. It should also be noted that rodents may not be a close model of weight regulation in humans. The effect of olanzapine, and not ziprasidone or risperidone, on rodent weight change in general appeared to be mediated at least in part by D2. 29 In D2-deficient mice, weight loss has been observed, along with increased oxygen consumption, decreased food intake and decreased plasma levels of leptin, an adipose hormone implicated in growth, glucose metabolism and reproduction. 30 An enhanced response to leptin, indicated by STAT3 phosphorylation, was observed. 30 Both conditional STAT3-deficient mice 31 and leptin receptor mutant mice 32 exhibit hyperglycemia and severe obesity. Results from studies on these genetically modified mice suggest that D2 may mediate olanzapine-and clozapineinduced weight gain through leptin-mediated STAT3 phosphorylation. In summary, DRD2 gene variants have been implicated in a variety of addictive disorders that are characterized by dysregulated intake of drugs and/or food and therefore the DRD2 gene appears to be a very good candidate for antipsychotic-induced weight gain, The DRD2, DRD3 and DRD4 genes have also been investigated in the 'opposite phenotype' of anorexia nervosa (reviewed in Rask-Andersen et al. 33 ). Bergen et al. 34 reported association between anorexia and four of seven DRD2 polymorphisms (À141C ins/del (rs1799732), C939T (rs6275), C957T and rs1800497). Specifically, the T (A1) allele was overrepresented in anorexia cases. 34 The only study that examined DRD3 Ser9Gly (rs6280) in anorexia nervosa was negative; however, other DRD3 polymorphisms were not tested. 35 Two studies have been reported on DRD4 in anorexia nervosa, 36, 37 and one reported significant association with two of five tested markers (C521T, 120 bp repeat; Bachner-Melman et al. 37 ). The DRD4 gene has been studied also in bulimia nervosa, with the seven repeat allele of the exon 3 variable-number tandem repeat (VNTR) being associated with binge eating and high lifetime body mass index. 38, 39 Of the five known dopamine receptor genes, only DRD2 (TaqIA) and DRD4 have been examined in antipsychoticinduced weight gain, with negative findings. 40, 41, 42 It is important to note that these investigations did not cover the genes using tag single nucleotide polymorphisms (SNPs). Therefore, in this study, we performed the first comprehensive examination between polymorphisms spanning the five dopamine receptor genes (DRD1, DRD2, DRD3, DRD4 and DRD5) and antipsychotic-induced weight gain.
Materials and methods

Subjects
A total of 206 patients with chronic schizophrenia or schizoaffective disorder were included in this study. Approval from the institutional ethics committee and informed consent was obtained for all the patients. The details of the sample are provided in Table 1 . Patients were recruited at three different sites-sample A: Charite University Medicine, Berlin, Germany (DJ Müller, I Puls, and A Heinz, n ¼ 67). Patients were diagnosed with schizophrenia or schizoaffective disorder according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) and ICD-10 criteria. Patients were started on antipsychotic medication and assessed prospectively for a period of up to 6 weeks. Sample B: Case Western Reserve University in Cleveland, Ohio (HY Meltzer, n ¼ 64) and Hillside Hospital in Glen Oaks, New York (JA Lieberman, n ¼ 16). Patients diagnosed with schizophrenia according to DSM-II Revised criteria who were either treatment refractory or intolerant to treatment with typical antipsychotic were included. Before starting treatment with clozapine there was a washout period of 2-4 weeks during which patients received no medications unless it was clinically essential. Clozapine dosage was not fixed and serum levels were monitored to ascertain compliance. Patients were treated with clozapine for 6 weeks and percent change in weight was calculated from baseline weight (for details see Masellis et al. 43 ). Sample C: (JA Lieberman, New York and North Carolina, n ¼ 59). Patients with chronic schizophrenia or schizoaffective disorder according to DSM-IV were included. These patients had shown suboptimal response to previous treatment with typical antipsychotic, mainly defined by persistent positive symptoms and a poor level of functioning over the past 2 years. Patients were randomly assigned to receive clozapine (500 mg per day), olanzapine (20 mg per day), risperidone (8 mg per day) or haloperidol in a 14-week double-blind study (for details, see Volavka et al.
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). Ethnicity was determined using genealogical information provided by the participants. Patients were classified by ethnicity if they did not report any admixture in the past three generations. Samples B and C are described in more detail in previous studies (for example, references 9, [45] [46] [47] ).
Genetic analysis
Genomic DNA was extracted from blood lymphocytes obtained from participants using the high-salt method. 48 All the genotyping was carried out using TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA, USA) except for VNTR polymorphism in the third exon of the DRD4 gene. Polymerase chain reactions (PCRs) of 10 ml were performed on 20 ng genomic DNA with the following conditions: 95 1C 10 min, followed by 50 cycles of 92 1C 15 s, 60 1C 1 min. Genotypes were determined using the ABI 7500 Sequence Detection System with the Allelic Discrimination software (Foster City, CA, USA). A total of 36 tag SNPs covering the five dopamine receptor genes (minor allele frequency40.20) were included in the study ( Figure 1 ). For the DRD4 exon 3 VNTR, genomic DNA was amplified with the following primer sequences: (5 0 -AGGACCCTCATGGCC TTG-3 0 and 5 0 -GCGACTACGTGGTCTACTCG-3 0 ) using previously described PCR conditions. 49 The amplified products were then resolved by 3.5% agarose gel electrophoresis and visualized by ethidium bromide staining. The sizes of the products were determined by comparison to the 100-bp DNA ladder (MBI Fermentas, Ontario, Canada).
Data analysis
Statistical analyses of individual polymorphisms were performed using SPSS 15.0 (Chicago, IL, USA). The categorical variable, the occurrence of at least 7% weight gain, was tested using the w 2 -test and the continuous variable, percentage weight change from baseline, was tested using analysis of variance. For the DRD4 exon 3 VNTR polymorphism, we analyzed for the presence and absence of the two-repeat, four-repeat or seven-repeat alleles separately. The Fisher's exact test was used in cases where expected cell counts were less than five, and Kruskal-Wallis test was used where analysis of variance was not appropriate due to heterogeneity of variance.
Linkage disequilibrium (LD) was determined using Haploview 4.0. 50 LD blocks were constructed using solid spine of LD. Haplotypes were analyzed using the UNPHASED 2.0 software, 51 with COCAPHASE routine for the occurrence of at least 7% weight gain and with QTPHASE routine for the percent change in weight. Only haplotypes with frequencies greater than 5% were included in the analyses. Power calculations were carried out using Quanto 1.2.4.
52 Assuming a minor allele frequency of 20% in a sample size of n ¼ 206, and a mean difference of 2.0 between carriers of the risk genotype, we had more than 80% power in an additive effect model. We also tested the allelic distribution of each polymorphism with occurrence of at least 7% weight gain for five subsets within our study sample (sample A, European descent; sample B, European descent; sample C, European descent; sample A, African American; sample B, African American) using a meta-analytic approach under a random model (Stata version 8 (StataCorp, College Station, TX, USA); for example Zai et al.
53
). For multiple testing correction, we consider the Bonferroni adjustment to be too stringent. Nonetheless, we provided P-values that were corrected by false discovery rate using the Signed Differential Mapping Web utilities (http://www.sdmproject.com/ utilities/?show ¼ FDR), and q-values using the qvality web server (http://rankprop.gs.washington.edu/tomcat/qvality/) 54 for the meta-analysis results (Supplementary Table S1c).
Results
Sample characteristics
All the SNPs were in Hardy-Weinberg equilibrium (P40.05). The clinical variables are different among the different sites; 55 Consistent with that, patients taking clozapine or olanzapine gained more weight than patients taking other antipsychotic medications (5.93±6.87 versus 3.73±5.64, P ¼ 0.0319). A sub-analysis was carried out, stratified for ethnicity (European or African origin) and antipsychotic medication (clozapine/olanzapine or risperidone/haloperidol).
Genetic analysis
There is a nominally significant association between the DRD2 rs1079598 marker and 7% weight gain yes/no (P ¼ 0.03). No association of any of the other polymorphisms with weight gain yes/no or weight change (%) was observed when we considered the total sample set (P40.05).
Of the 37 polymorphisms, three DRD2 SNPs rs6277 (C957T), rs1079598 and rs1800497 (TaqIA), showed either a significant association or a trend with antipsychotic-induced weight gain in the European Americans taking clozapine or olanzapine (n ¼ 85; Figures 1 and 2 ; Supplementary Table S1 ).
Specifically, C957T (rs6277) was associated with both the occurrence of weight gain (Figure 1 ; Supplementary Table S1a) and percentage weight change (Figure 2 ; Supplementary Table S1a ). Carriers of the CC genotype were more likely to have gained at least 7% weight (odds ratio (OR) CC ¼ 3.37, 95% confidence interval (CI): 1.00-11.36) and gained more weight (6.59±4.82%) than the C allele (CT or TT) carriers (4.22 ± 5.85%). We observed the same trend for the C957T 1  rs4532  rs686  rs265976  rs1799978  rs1799732  rs4630328  rs4648317  rs7131056  rs4274224  rs17529477  rs1079598  rs1076563  rs1800498  rs6275  rs6277  rs2234689  rs1800497  rs905568  rs7620754  rs2399504  rs7611535  rs1394016  rs9825563  rs1800828  rs6280  rs7633291  rs167770  rs2134655  rs2399496  rs2087017  rs1025398  rs3758653 exon3-VNTR rs11246226 rs10033951 rs6283 rs10001006
Figure 1 Summary plot of P-values from analysis of occurrence of at least 7% weight gain with polymorphisms in dopamine receptor DRD1, DRD2, DRD3, DRD4 and DRD5 genes. Results from genotypic, allelic and two-marker haplotypic analyses are shown. The significance threshold of 0.05 is also shown. The schematic diagrams of each of the five dopamine receptor genes are shown in the middle, followed by linkage disequilibrium structures derived from the subset of patients of European ethnic origin at the bottom.
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polymorphism in African Americans taking clozapine or olanzapine and a significant association with increase weight gain and the C allele (P ¼ 0.03; n ¼ 41; Supplementary Table S1b ). We also found the C allele of DRD2 rs1079598 to be significantly overrepresented in the patient group with at least 7% weight gain (OR CC_or_CT ¼ 3.08, 95% CI: 1.12-8.47; OR C ¼ 3.44, 95% CI: 1.46-8.11; Supplementary Table S1a) .
The DRD2 TaqIA A1 (T) allele was also associated with 7% weight gain in patients of European ancestry taking clozapine or olanzapine (OR T ¼ 2.18, 95% CI: 1.00-4.75; Supplementary Table S1a) .
Because our overall sample was collected from a number of clinical sites with potential differences in recruitment procedures, we attempted to address this heterogeneity by conducting an additional meta-analytic approach of the results, separating the sample of patients (taking clozapine or olanzapine) according to recruitment sites and ethnicity, and found the C957T C allele to be associated with risk for at least 7% weight gain (false discovery rate P ¼ 0.004; Figure 3 ; Supplementary Table S1c) . The meta-analysis also uncovered a nominally significant association with the DRD2 rs7131056 marker.
Finally, we also analyzed two-marker haplotypes across each dopamine receptor gene using the sliding window approach (Figures 1 and 2 ). The C-C haplotype of C957T and rs2234689 was overrepresented in the weight gain group (window global P ¼ 0.025, OR CÀC ¼ 3.17, 95% CI: 1.48-6.78, haplotype-specific P ¼ 0.006) and was associated with higher percentage weight gain (window (Figures 1 and 2) .
Discussion
This is the first systematic investigation of polymorphisms across all five of the dopamine receptor genes in antipsychotic-induced weight gain.
In the entire sample, we observed a significant association with marker rs1079598 of the DRD2 gene. However, as weight gain was shown to vary according to type of medication and ethnic background, meaningful results are only likely to be observed after stratifying the sample into In the sample of patients with European ancestry, we found significant findings with three DRD2-related polymorphisms, C957T, TaqIA and rs1079598. It is important to note that our sample was recruited from multiple clinical sites, the issue that was addressed by the additional metaanalysis of our data. The meta-analytic approach (taking into consideration the different recruitment sites, ethnicities and clozapine/olanzapine-treated patients) revealed a significant finding for the rs7131056 polymorphism.
The most interesting findings are probably those related to the DRD2 C957T polymorphism, as the results are positive for both occurrence of at least 7% weight gain and percentage weight change. Despite only showing trends in the genotypic analyses, both allelic analyses were significant in the European and African-American sample indicating that the C allele or C/C genotype confers increased risk for weight gain. Haplotype analyses also revealed significant findings involving this SNP. Moreover, these findings also turned out to be significant when using the meta-analytic approach. In addition, although this polymorphism does not affect the amino-acid sequence of the D2 receptor protein, the T variant is associated with decreased striatal D2 affinity in vivo and decreased DRD2 mRNA stability and halflife in vitro. 56, 57 Our genetic findings suggest that increased D2 levels predict risk for clinically relevant weight gain (almost 6 kg of body increase in 6-14 weeks of treatment). These findings appear to be in contrast to previous findings of D2 levels inversely correlated to body mass index. However, here we are testing an association between dopamine receptor genes and weight gain in the context of antipsychotic treatment. Among individuals carrying this risk genotype, increased D2 levels could translate into more targets for antipsychotics to antagonize and may thus result in a relatively greater inhibition of intracellular signaling downstream of dopamine D2 receptor.
Findings with the DRD2-related TaqIA polymorphism are also interesting as they are in agreement with previous genetic studies of obesity and considering that this polymorphism may be of functional relevance. 57 It is important to note that TaqIA has been shown to be situated in the coding region of the nearby ankyrin repeats and kinase domain containing 1 (ANKK1) gene, where it causes an amino-acid substitution in the last ankyrin repeat. 58, 59 It is possible that the TaqIA polymorphism is either in LD with a functional polymorphism in DRD2, or that ANKK1 affects signal transduction within the dopaminergic system. 60 The role for ANKK1 gene polymorphisms in addiction has also been implicated, 61 however further replication studies and functional analyses are required to strengthen these previous genetic findings on addiction. Given that the results with TaqIA were only significant in Europeans with African Americans showing a different weight gain distribution, further studies are required in larger samples to confirm these findings.
As for the rs1079598, the minor allele frequency was low and the results need further confirmation in larger samples, however, the most significant haplotypic finding was found for this marker.
The remaining SNP, rs7131056, was only one significant in the meta-analytic approach, and similar to rs1079598, functional consequences have not been reported. Nonetheless, these exploratory findings may serve as stimulus for replication studies.
The pathway through which D2 could mediate antipsychotic-induced weight gain requires further investigation. Generally, most if not all antipsychotic medications antagonize D2 receptors, with suggested important differences in terms of the dissociation from D2 receptors between typical and atypical antipsychotics. 62 On the basis of concept of dopamine as important neurotransmitter in motivation and reward processes, 12, 63 one would expect that antagonism of the dopaminergic system may lead to reduced motivation for reward-associated cues such as food intake. Indeed, patients often dislike particularly typical antipsychotics due to their ability to decrease motivation and pleasure. 64, 65 However, a general reduction in neuronal activation elicited by reward-predicting stimuli can be associated with an increased neuronal activation elicited by drugs of abuse, which are able to stimulate dopamine release even in a downregulated system because of their pharmacological properties. 66 Similarly, high-caloric food seems to reduce dopaminergic neurotransmission in rodents, which appears to contribute to preference of high-versus low-caloric food, hypothetically because of the stronger effects of high-caloric food on the downregulated dopamine system. 13 Therefore, second-generation antipsychotics may also induce general dysfunctions in the reward system, while increasing motivation for food and drugs that directly stimulate dopamine release (for example, high-caloric food, nicotine or cannabis). Interestingly, in a functional magnetic resonance imaging study, healthy volunteers and patients with schizophrenia showed ventral striatal activation in response to reward-indicating cues only when treated with atypical antipsychotics, whereas schizophrenia patients treated with typical neuroleptics did not. 64, 65 Thus, it can be hypothesized that in some individuals, atypical antipsychotics may increase the reward value for palatable food and subsequently lead to increased weight gain.
Of note, in one of our previous studies we observed the C957T polymorphism to be associated with occurrence of tardive dyskinesia, a side effect induced mainly by typical antipsychotic drugs characterized by abnormal involuntary movements. 66 Similarly, the C allele was associated with higher risk for tardive dyskinesia and it appears that the C957T polymorphism could be associated more broadly with tolerability of antipsychotics, where C-allele carriers have a higher risk for adverse events. This is similar to carriers of the S allele of the serotonin transporter gene who have higher rates of adverse events.
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Finally, we also found a signal for the rs7620754 marker in the 5 0 region of the DRD3 gene in our quantitative and haplotypes analyses. Whether this SNP is associated with DRD3 gene function remains to be explored.
In summary, this study provides suggestive evidence that gene variants of the DRD2 and possibly also of the DRD3 are involved in antipsychotic-induced weight gain.
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